Correlation Between Rezolute and Molecular Partners
Can any of the company-specific risk be diversified away by investing in both Rezolute and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Rezolute and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Rezolute and Molecular Partners AG, you can compare the effects of market volatilities on Rezolute and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Rezolute with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Rezolute and Molecular Partners.
Diversification Opportunities for Rezolute and Molecular Partners
0.29 | Correlation Coefficient |
Modest diversification
The 3 months correlation between Rezolute and Molecular is 0.29. Overlapping area represents the amount of risk that can be diversified away by holding Rezolute and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Rezolute is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Rezolute are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Rezolute i.e., Rezolute and Molecular Partners go up and down completely randomly.
Pair Corralation between Rezolute and Molecular Partners
Given the investment horizon of 90 days Rezolute is expected to under-perform the Molecular Partners. But the stock apears to be less risky and, when comparing its historical volatility, Rezolute is 1.82 times less risky than Molecular Partners. The stock trades about -0.19 of its potential returns per unit of risk. The Molecular Partners AG is currently generating about -0.08 of returns per unit of risk over similar time horizon. If you would invest 646.00 in Molecular Partners AG on August 28, 2024 and sell it today you would lose (84.00) from holding Molecular Partners AG or give up 13.0% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Rezolute vs. Molecular Partners AG
Performance |
| Timeline |
| Rezolute |
| Molecular Partners |
Rezolute and Molecular Partners Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Rezolute and Molecular Partners
The main advantage of trading using opposite Rezolute and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Rezolute position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.The idea behind Rezolute and Molecular Partners AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.| Molecular Partners vs. Mineralys Therapeutics, Common | Molecular Partners vs. AN2 Therapeutics | Molecular Partners vs. Pharvaris BV | Molecular Partners vs. PepGen |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Complementary Tools
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |